Novartis Ag (NVS) Research & Development (2009 - 2026)
Novartis Ag (NVS) posted Research & Development of $2.8 billion for Q2 2026, up 4.4% sequentially from $2.7 billion in Q2 2025, and up 4.4% YoY from $2.7 billion in Q2 2025.
Novartis Ag (NVS) Research & Development (2009 - 2026) Analysis & Trends
Novartis Ag has reported Research & Development for 18 years, with the latest figure at $2.8 billion in Q2 2026.
- Quarterly Research & Development rose 4.4% year-over-year to $2.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.6 billion (up 83.01% YoY) and the FY2025 annual result came in at $11.2 billion, up 11.75% from the prior year.
- Research & Development climbed to $2.8 billion in Q2 2026 per NVS's latest filing, from $2.7 billion in the prior quarter.
- Over five years, Research & Development peaked at $2.8 billion in Q2 2026 and troughed at -$4.9 billion in Q4 2023.
- A 5-year average of -$1.5 billion and a median of -$2.3 billion in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development dropped 5.29% in 2023, then soared 215.21% in 2025.
- Over 5 years, Research & Development stood at -$4.8 billion in 2022, then retreated by 1.27% to -$4.9 billion in 2023, then gained by 1.87% to -$4.8 billion in 2024, then surged by 156.95% to $2.7 billion in 2025, then gained by 4.4% to $2.8 billion in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $2.8 billion, $2.7 billion, and -$4.8 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.85 Bn |
| Jun 30, 2025 | 2.73 Bn |
| Dec 31, 2024 | -4.79 Bn |
| Jun 30, 2024 | -2.37 Bn |
| Dec 31, 2023 | -4.88 Bn |
| Jun 30, 2023 | -2.30 Bn |
| Mar 31, 2023 | -219.00 Mn |
| Dec 31, 2022 | -4.82 Bn |
| Sep 30, 2022 | -194.00 Mn |
| Jun 30, 2022 | -2.50 Bn |
| Mar 31, 2022 | -208.00 Mn |
| Dec 31, 2021 | -4.75 Bn |
| Sep 30, 2021 | -224.00 Mn |
| Jun 30, 2021 | -2.40 Bn |
| Mar 31, 2021 | -214.00 Mn |
| Dec 31, 2020 | -4.50 Bn |
| Sep 30, 2020 | -216.00 Mn |
| Jun 30, 2020 | -2.44 Bn |
| Mar 31, 2020 | -194.00 Mn |
| Jun 30, 2019 | -2.05 Bn |